Stoke Therapeutics, Inc., an early-stage biopharmaceutical company, develops novel antisense oligonucleotide (ASO) medicines to treat the underlying causes of severe genetic diseases in the United States. The company utilizes its proprietary ribonucleic acid therapeutics platform, Targeted Augmentation of Nuclear Gene Output (TANGO), to design ASOs to upregulate the expression of protein by individual genes in a patient. Its lead product candidate is STK-001 that is used to treat Dravet syndrome, a severe and progressive genetic epilepsy. The company was formerly known as ASOthera Pharmaceuticals, Inc. and changed its name to Stoke Therapeutics, Inc. in May 2016. Stoke Therapeutics, Inc. was incorporated in 2014 and is headquartered in Bedford, Massachusetts.
IPO Year: 2019
Exchange: NASDAQ
Website: stoketherapeutics.com
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 10/14/2024 | $18.00 | Outperform | Leerink Partners |
| 3/26/2024 | Market Perform → Outperform | TD Cowen | |
| 11/20/2023 | Neutral | JP Morgan | |
| 7/25/2023 | Outperform → Market Perform | TD Cowen | |
| 5/1/2023 | $9.00 → $12.00 | Underperform → Neutral | BofA Securities |
| 4/26/2023 | $24.00 | Buy | Canaccord Genuity |
| 1/6/2023 | $22.00 → $9.00 | Buy → Underperform | BofA Securities |
| 10/24/2022 | $30.00 | Mkt Perform → Outperform | SVB Leerink |
| 1/31/2022 | $50.00 | Buy | Jefferies |
| 12/3/2021 | $43.00 | Buy | B of A Securities |
– Company plans to provide seizure as well as cognition and behavior data from all patients treated with initial 70mg doses followed by 45mg maintenance dosing in studies of zorevunersen by year-end – – Discussions with FDA and global regulatory agencies related to a single global Phase 3 study of zorevunersen continue to progress; Company to provide an update by year-end – – As of September 30, 2024, Company had $269.2 million in cash, cash equivalents, and marketable securities – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today reported financial results for the third qu
– New data showed improvements in cognition and behavior during the first year of treatment with additional increases demonstrated as treatment continued – – Clinical effects observed across the Phase 1/2a and open-label extension studies (OLEs) of zorevunersen are a first in the treatment of Dravet syndrome and support plans for the Company's Phase 3 registrational study – – Zorevunersen generally well-tolerated across the studies – – Data presented for the first time at the 15th European Epilepsy Congress (EEC) – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announce
– Mr. Olson brings two decades of successful corporate business development experience with an emphasis on rare diseases and RNA therapeutics – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced the appointment of Eric Olson as Chief Business Officer. Mr. Olson has two decades of experience in life sciences business development and strategy with a track record of success, completing numerous transactions to maximize value for company pipelines across a variety of therapeutic areas, including rare genetic diseases, neurology and ophthalmology. In his new role, Mr. Ol
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that management will present at the following upcoming investor conferences: H.C. Wainwright 26th Annual Global Investment Conference Date: Tuesday, September 10, 2024 Time: 12:00 p.m. ET 2024 Cantor Fitzgerald Global Healthcare Conference Date: Tuesday, September 17, 2024 Time: 11:30 a.m. ET Live webcasts of each event and an archived replay of the webcasts following each event, will be available on the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. About Stoke Therape
– First presentation of landmark data from Phase 1/2a and OLE studies of zorevunersen that showed substantial reductions in seizures and continued improvements in multiple measures of cognition and behavior – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced it will present data from its Dravet syndrome clinical program at the 15th European Epilepsy Congress (EEC) taking place September 7 – 11, in Rome, Italy. The Company is advancing zorevunersen (STK-001), a proprietary antisense oligonucleotide (ASO), as the first potential medicine to address the genetic caus
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that, effective on August 15, 2024, the company granted stock options to purchase an aggregate of 48,400 shares of common stock to three new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $14.25 per share, which is equal to the closing price of Stoke's common stock on August 15, 2024. Each option will vest over a 4-year period, with 1/4th of the shares underlying the employee's option vesting on
– FDA removes Partial Clinical Hold as company advances toward a Phase 3 registrational study of zorevunersen (STK-001) in children and adolescents with Dravet syndrome – – Company to provide an update on Phase 3 registrational plans for zorevunersen in the second half of 2024 – – Company on track to initiate the Phase 1 study (OSPREY) of STK-002 for the treatment of Autosomal Dominant Optic Atrophy (ADOA) this year – – As of June 30, 2024, Company had $282.0 million in cash, cash equivalents, and marketable securities – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, toda
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced that, effective on July 15, 2024, the company granted stock options to purchase an aggregate of 122,900 shares of common stock to three new employees, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $14.58 per share, which is equal to the closing price of Stoke's common stock on July 15, 2024. Each option will vest over a 4-year period, with 1/4th of the shares underlying the employee's option vesting on the
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that, effective on June 17, 2024, the company granted stock options to purchase an aggregate of 10,400 shares of common stock to one new employee, as a material inducement to their employment in accordance with Nasdaq Listing Rule 5635(c)(4). The stock options that were granted have an exercise price of $15.60 per share, which is equal to the closing price of Stoke's common stock on June 17, 2024. Each option will vest over a 4-year period, with 1/4th of the shares underlying the employe
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will present at the following upcoming investor conferences: Goldman Sachs 45th Annual Global Healthcare Conference Date: Monday, June 10, 2024 Time: 4:00 p.m. ET TD Cowen Genetic Medicines & RNA Summit Date: Thursday, June 20, 2024 Time: 10:00 a.m. ET Live webcasts of each event and an archived replay of the webcasts following each event, will be available on the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. About Stoke The
10-Q - Stoke Therapeutics, Inc. (0001623526) (Filer)
8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)
S-3ASR - Stoke Therapeutics, Inc. (0001623526) (Filer)
8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)
10-Q - Stoke Therapeutics, Inc. (0001623526) (Filer)
8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)
8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)
EFFECT - Stoke Therapeutics, Inc. (0001623526) (Filer)
S-3 - Stoke Therapeutics, Inc. (0001623526) (Filer)
8-K - Stoke Therapeutics, Inc. (0001623526) (Filer)
– Totality of data from these ongoing studies suggest clinical benefit for patients ages 2 to 18 years old, including reductions in seizures and improvements in cognition and behavior that support the potential for disease modification – – Phase 1/2a ADMIRAL Study Data STK-001 (70mg): Patients treated with 2 or 3 initial doses experienced substantial and sustained reductions in convulsive seizure frequency; Median reductions at 3 months after last dose (n=6) of 80% and 89% (n=3) at 6 months after last dose, compared to baseline – – OLE Study Data STK-001 (30mg, 45mg): Sustained reductions in convulsive seizure frequency and improvements in cognition and behavior – – MONARCH & ADMIRAL
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will hold a webinar and conference call for analysts and investors at 8:00 a.m. Eastern Time on Tuesday, July 25, 2023, to present new data from the two ongoing Phase 1/2a studies (MONARCH and ADMIRAL) and the SWALLOWTAIL open-label extension study in children and adolescents with Dravet syndrome. The webinar will be broadcast live on the Investors & News section of Stoke's website at https://investor.stoketherapeutics.com/. Participants who want to join the call and ask
– Company announces positive interim data from the ongoing Phase 1/2a clinical studies of STK-001 in children and adolescents with Dravet syndrome – – Single and multiple doses of STK-001 up to 45mg were well-tolerated – – 55% median reduction from baseline in convulsive seizure frequency was observed among patients treated with three doses of 45mg – – In 2023 the Company plans to report data from more patients treated with multiple doses of 45mg as well as those treated with multiple doses of 70mg – – As of September 30, 2022, Company had $252.2 million in cash, cash equivalents, marketable securities, and restricted cash, anticipated to fund operations into 2025 – – Management will h
Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced that management will hold a webinar and conference call for analysts and investors at 8:30 a.m. Eastern Time on Monday, November 14, 2022, to present data from a planned interim analysis of the Phase 1/2a studies of STK-001 in children and adolescents with Dravet syndrome. To participate in the call, please dial (800) 715-9871, or (646) 307-1963 for international callers and provide conference call ID number 2168761. The webinar will be broadcast live on the Investors & News section of St
– Results show that single doses of STK-001 up to 30mg and multiple doses of 20mg were well-tolerated with no safety concerns related to the study drug – – A trend toward a reduction in convulsive seizure frequency was observed among patients treated with single doses of STK-001 – – >95% of patients anticipated to achieve pharmacologically active levels of STK-001 with three monthly doses of 30mg – – Complementary Phase 1/2a studies ongoing; First patients dosed in the 30mg multiple ascending dose (MAD) cohorts of MONARCH in the U.S. and ADMIRAL in the UK – – FDA will allow the evaluation of an additional higher dose level (45mg) in the MONARCH study – – Management will host a webinar
Leerink Partners resumed coverage of Stoke Therapeutics with a rating of Outperform and set a new price target of $18.00
TD Cowen upgraded Stoke Therapeutics from Market Perform to Outperform
JP Morgan resumed coverage of Stoke Therapeutics with a rating of Neutral
TD Cowen downgraded Stoke Therapeutics from Outperform to Market Perform
BofA Securities upgraded Stoke Therapeutics from Underperform to Neutral and set a new price target of $12.00 from $9.00 previously
Canaccord Genuity resumed coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $24.00
BofA Securities downgraded Stoke Therapeutics from Buy to Underperform and set a new price target of $9.00 from $22.00 previously
SVB Leerink upgraded Stoke Therapeutics from Mkt Perform to Outperform and set a new price target of $30.00
Jefferies initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $50.00
B of A Securities initiated coverage of Stoke Therapeutics with a rating of Buy and set a new price target of $43.00
SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
SC 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)
SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
SC 13D/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
SC 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)
SC 13D/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
SC 13G/A - Stoke Therapeutics, Inc. (0001623526) (Subject)
SC 13G - Stoke Therapeutics, Inc. (0001623526) (Subject)
Wedbush analyst Laura Chico reiterates Stoke Therapeutics (NASDAQ:STOK) with a Outperform and maintains $17 price target.
Ratings for Stoke Therapeutics (NASDAQ:STOK) were provided by 5 analysts in the past three months, showcasing a mix of bullish and bearish perspectives. The table below offers a condensed view of their recent ratings, showcasing the changing sentiments over the past 30 days and comparing them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 5 0 0 0 0 Last 30D 1 0 0 0 0 1M Ago 0 0 0 0 0 2M Ago 3 0 0 0 0 3M Ago 1 0 0 0 0 Analysts have set 12-month price targets for Stoke Therapeutics, revealing an average target of $24.2, a high estimate of $35.00, and a low estimate of $20.00. Experiencing a 3.2% decline, the current aver
Needham analyst Joseph Stringer reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $22 price target.
With U.S. stock futures trading slightly higher this morning on Monday, some of the stocks that may grab investor focus today are as follows: Wall Street expects Enerpac Tool Group Corp. (NYSE:EPAC) to report quarterly earnings at 47 cents per share on revenue of $153.20 million after the closing bell. Enerpac Tool Group shares gained 1.9% to $39.22 in after-hours trading. Singular Genomics Systems, Inc. (NASDAQ:OMIC) reported a 1-for-30 reverse stock split. Singular Genomics shares fell 9.3% to $0.3180 in the after-hours trading session. Analysts are expecting Beyond Air, Inc. (NASDAQ:XAIR) to post a quarterly loss at $0.48 per share on revenue of $747.20 thousand. The company wil
- Form 8-K
Canaccord Genuity analyst Sumant Kulkarni maintains Stoke Therapeutics (NASDAQ:STOK) with a Buy and lowers the price target from $21 to $20.
HC Wainwright & Co. analyst Andrew Fein reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $35 price target.
Stoke Therapeutics (NASDAQ:STOK) underwent analysis by 8 analysts in the last quarter, revealing a spectrum of viewpoints from bullish to bearish. Summarizing their recent assessments, the table below illustrates the evolving sentiments in the past 30 days and compares them to the preceding months. Bullish Somewhat Bullish Indifferent Somewhat Bearish Bearish Total Ratings 6 1 1 0 0 Last 30D 1 0 0 0 0 1M Ago 1 0 0 0 0 2M Ago 3 1 1 0 0 3M Ago 1 0 0 0 0 Analysts have recently evaluated Stoke Therapeutics and provided 12-month price targets. The average target is $20.75, accompanied by a high estimate of $35.00 and a low estimate of $13.00. Witnessing a positive shift, the c
Needham analyst Joseph Stringer reiterates Stoke Therapeutics (NASDAQ:STOK) with a Buy and maintains $22 price target.
Stoke Therapeutics (NASDAQ:STOK) reported quarterly losses of $(0.57) per share which beat the analyst consensus estimate of $(0.61) by 6.56 percent. The company reported quarterly sales of $4.216 million which beat the analyst consensus estimate of $3.214 million by 31.16 percent. This is a 23.51 percent decrease over sales of $5.512 million the same period last year.
– Mr. Olson brings two decades of successful corporate business development experience with an emphasis on rare diseases and RNA therapeutics – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to restoring protein expression by harnessing the body's potential with RNA medicine, today announced the appointment of Eric Olson as Chief Business Officer. Mr. Olson has two decades of experience in life sciences business development and strategy with a track record of success, completing numerous transactions to maximize value for company pipelines across a variety of therapeutic areas, including rare genetic diseases, neurology and ophthalmology. In his new role, Mr. Ol
– Mr. Hoitt brings more than two decades of successful commercial experience with an emphasis on rare diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Jason Hoitt as Chief Commercial Officer. Mr. Hoitt has more than 20 years of experience successfully planning and executing commercial strategies at leading biopharma companies. As Chief Commercial Officer and a member of Stoke's leadership team, Mr. Hoitt will be responsible for overseeing the Company's global commercial strategy for STK-001. Recently annou
– Mr. Smith brings significant experience in the successful development and commercialization of medicines for rare genetic diseases – Stoke Therapeutics, Inc. (NASDAQ:STOK), a biotechnology company dedicated to addressing the underlying cause of severe diseases by upregulating protein expression with RNA-based medicines, today announced the appointment of Ian Smith to its Board of Directors effective September 19. "Ian brings more than two decades of significant executive management experience in the life sciences industry, with a strong track record of successfully building valuable biotech businesses," said Edward M. Kaye, M.D., Chief Executive Officer of Stoke Therapeutics. "His div
Nuvig Therapeutics, Inc., a biopharma company developing proprietary recombinant human therapeutics for patients with autoimmune diseases, today announced the appointment of Julie Anne Smith as Chief Executive Officer (CEO) and member of the Board of Directors. Ms. Smith has over 20 years of experience in the life science industry, with a focus on leading private and public biotech companies through development and commercialization of therapeutics for orphan diseases. Pamela Conley, Ph.D., cofounder and founding CEO of Nuvig Therapeutics, will serve as the Company's Chief Scientific Officer. "The board is very grateful to Pam for leading Nuvig from inception to this exciting inflection po
4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)
4 - Stoke Therapeutics, Inc. (0001623526) (Issuer)